- 1 **Supporting Information for:**
- 2 **A Fluorescence Displacement Assay for Antidepressant Drug Discovery Based on Ligand**
- 3 **Conjugated Quantum Dots**
- $\frac{4}{5}$

5 *Jerry C. Chang, Ian D. Tomlinson, Michael R. Warnement, Hideki Iwamoto, Louis J. DeFelice,*  6 *Randy D. Blakely, and Sandra J. Rosenthal* 

7 8 *Experimental Section* 

### 9 **IDT318 Ligand synthesis**

10 The synthesis details and spectroscopic characterization have been previously described in 11 our recent publications.<sup>1,2</sup> [B](#page-7-0)rief outline is shown in the scheme below. Initially, the parent drug 12 5-methoxy-3-(1,2,5,6-tetrahydro-4-pyridinyl)-1*H*-indole **(1)** was synthesized and coupled to 13 11-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-undecyl bromide **(2)** to yield 2-(11-(4-(5-methoxy-14 1*H*-indol-3yl)-5,6-dihydropyridin-(2*H*)-yl)undecyl) isoindoline-1,3-dione **(3)** in the presence of 15 triethylamine  $(Et<sub>3</sub>N)$ . The phthalimide protecting group was removed using hydrazine 16 monohydrate to give 11-(4-(5-methoxy-1*H*-indol-3-yl)-5,6-dihydropyridin-1(2*H*)-yl)undecan-1-

- 17 amine **(4).** This is then coupled to biotin-polyethylene glycol-*N*-hydroxysuccinimide ester to give
- 18 the SERT ligand IDT318 **(5)** for the study.



- 19
- 20

# 21 **hSERT-espressing oocytes prepapation**

22 *Xenopus* oocytes and hSERT cRNA were prepared and isolated as previously described.<sup>[3,4](#page-7-0)</sup> 23 In brief, stage V-VI oocytes were harvested from *Xenopus laevis* (Nasco, Medesto, CA). After 24 harvesting, the follicle cell layer was removed by incubation with 2 mg/ml collagenase in 25 Ringer's buffer (in mM, 96 NaCl, 2 KCl, 5 MgCl<sub>2</sub>, 5 HEPES, pH 7.4) for an hour. cRNA 26 injections were performed on the day of harvest. hSERT cRNA was transcribed from NotI (New 27 England BioLabs, Beverly, MA)-digested cDNA in pOTV vector (a gift of Dr. Mark Sonders,

1 Columbia University) using Ambion mMessage Machine T7 kit (Ambion, Austin, TX). The 2 cRNA concentrations were confirmed by UV spectroscopy and gel electrophoresis. Each oocyte 3 was injected with 3 ng cRNA and incubated at 18 C° for 3-6 days in Ringer's buffer 4 supplemented with 550  $\mu$ M/ml sodium pyruvate, 100  $\mu$ g/ml streptomycin, 50  $\mu$ g/ml tetracycline, 5 and 5 % dialyzed horse serum. Healthy oocytes for subsequent electrophysiological and 6 fluorescence assays were selected by visual inspection.

7

# 8 **Quantum dot-hSERT labeling and displacement in oocytes**

9 For two-step QD-SERT labeling, oocytes were first incubated with 1  $\mu$ M biotinylated ligand 10 in PBS for 60 minutes prior to 5 minutes incubation of 2.5 nM SA-QD (Qdot® 655 streptavidin 11 conjugate, Invitrogen, Carlsbad, CA).

12 The pre-incubation affinity assay (Fig. 2 column 3 and 4).was demonstrated using 13 paroxetine and 5-HT as testing drugs. In pre-incubation affinity assay, oocytes were first 14 incubated with testing drug (1 µM for paroxetine; 1 mM for 5-HT) in PBS for 60 minutes, 15 followed by a ligand/drug mixture incubation (1 µM/1 µM for paroxetine; 1 µM/1 mM for 5-HT) 16 in PBS for another 60 minutes, and then finally incubated with 2.5 nM SA-QD for 5 minutes. 17 After QD labeling, single oocytes were transferred to 8-well Lab-Tek chamber slides (NUNC, 18 Roskilde, Denmark) and imaged in PBS. Excess ligand, drug, and QD were removed by two 19 washes with PBS at each step. 20 For time course displacement assay demonstrated in Fig. 3, selected single hSERT

21 expressing oocyte was transferred to one well of Lab-Tek 8-well chamber slide after processing 22 two-step QD-SERT labeling, each well contain either 0  $\mu$ M (control), 10  $\mu$ M or 20  $\mu$ M of 23 paroxetine in 400 µL PBS. A time series of fluorescent images was immediately acquired at a 1 24 minute interval over a 30 minute period. 25

26 **Microscopy** 

27 Confocal images were obtained on a Zeiss LSM 510META confocal imaging system (Carl 28 Zeiss Microimaging, Inc., Thornwood, NY). Images were collected using a Zeiss 29 Plan-Apochromat 5×/0.16 numerical aperture (NA) objective lens and excited by an argon laser 30 at 458 nm with 25% transmission rate and pinhole was set to 2 Airy units. All images were 31 512×512 pixels in size and had an 8-bit pixel depth. For single ligand labeling experiments, 32 fluorescence signal was collected on photomultiplier-tube (PMT) detector after passing through a 33 650 nm cutoff filter to ensure the transmission of only the Qdot 655 signal.

34 Wide-field fluorescent images were acquired using a Zeiss Axiovert 200 M inverted  $135$  fluorescence microscope equipped with a Photometrics Cool-Snap<sup>TM</sup> HQ2 electrically cooled 36 CCD camera (Intelligent Imaging Innovations, Denver, CO), a Zeiss Plan-Neofluar 20×/0.4 37 numerical aperture (NA) objective lens and QD655 filter set (XF 1002 filter, Omega Optical, 38 Brattleboro, VT). Exposure time was set at 200 ms for all fluorescent imaging. Image acquisition 39 and analysis was processed using Metamorph® 7 imaging software (Molecular Devices Corp.; 40 Downingtown, PA).

41

# 42 **Two-electrode voltage-clamp electrophysiological analysis**

43 Whole-cell currents were measured with two electrode voltage clamp techniques using a 44 GeneClamp 500 (Molecular Devices, Palo Alto, CA). Microelectrodes were pulled using a 45 programmable puller (Model P-87, Sutter Instrument, Novato, CA) and filled with 3 M KCl 46 (0.5-5 MΩ resistance). A 16-bit A/D converter (Digidata 1322A, Molecular Devices) interfaced

1 to a PC computer running Clampex 9 software (Molecular Devices) was used to control 2 membrane voltage and to acquire data. To induce hSERT-associated current, serotonin was 3 dissolved (typically 10 µM) in a buffer solution (in mM, 120 NaCl, 5.4 potassium gluconate, 1.2 4 calcium gluconate, 7.2 HEPES, pH 7.4) and applied to oocytes using a gravity-flow perfusion 5 system (4-5 ml/min flow rate). Serotonin-induced current is defined by subtraction of current in 6 the presence of serotonin from current in the absence of serotonin. For recordings, data were 7 low-pass filtered at 10 Hz and digitized at 20 Hz. Analyses were performed using Origin 7 8 (Origin Lab, Northampton, MA).

9

#### 10 **Data Analysis**

11 For displacement assays, each time-series of wide-field fluorescence images was analyzed 12 using Metamorph's active region measurement program. Briefly, an initial active region was 13 selected from the membrane halo region of the fluorescent image, and this same region was 14 applied to each fluorescence image for subsequent time flame. The correlation of background 15 signal was performed by subtracting the result from the background image on a pixel-by-pixel 16 basis. Background signal of the CCD detector was measured by taking the fluorescence image 17 under the same experimental setup without sample loading. Data were measured as relative 18 fluorescent units (RFUs) and normalized to the following equation:

$$
normalized response = \frac{F_t}{F_0}
$$
 (Eq. 1)

20 where  $F_t$  is the fluorescent signal generated in the presence of paroxetine at time t;  $F_0$  is the 21 initial fluorescent intensity generated in the absence of paroxetine.

22 Data were evaluated by fitting to either a linear or single exponential equation for control 23 experiment and Paroxetine displacing experiment, respectively. For the control experiment, each 24 time course data points were fit into a linear curve regression equation:

25 
$$
\frac{F_t}{F_0} = \frac{F_{\infty}}{F_0} + A \cdot t
$$
 (Eq. 2)

26 where  $F_t$  is the fluorescent signal generated in the presence of paroxetine at time *t*;  $F_0$  is the 27 initial fluorescent intensity generated in the absence of paroxetine, *F*∞ is the fluorescent intensity 28 at infinite time, and *A* represents amplitude. For the paroxetine displacing experiment, the time 29 courses were fit into a single-exponential equation:

30 
$$
\frac{F_t}{F_0} = \frac{F_{\infty}}{F_0} + B \cdot e^{-k_{app} \cdot t}
$$
 (Eq. 3)

31 where  $F_t$  is the fluorescent signal generated in the presence of paroxetine at time *t*;  $F_0$ , the initial 32 fluorescent intensity generated in the absence of paroxetine; *F*∞, the fluorescent intensity at 33 infinite time; *kapp*, the apparent rate constant; *B*, the amplitude. All the fitting curves were  $34$  generated by using Sigmaplot<sup>TM</sup> software (Version 11.2, Systat Software Inc., San Jose, CA).

35 Measurements of each reaction kinetics for QD-based displacement assays were performed 36 by taking the natural logarithm of each time courses fluorescent data point generated from the 37 paroxetine displacing experiments and then plotted as a function of time. First-order dissociation 38 was evaluated by fitting the 0-10 minute data points to the linear curve regression using 39 Sigmaplot software.

40 Note that the SA-QDs we used in this study have potentially 4-10 streptavidins/QD, 41 suggesting a possible 16-40 binding sites/QD.<sup>5</sup> A recent study reported that this particular kind of 42 SA-QDs has  $\sim$  5 biotin binding sites/QD.<sup>6</sup> As can be seen in Fig. 3B, the dissociation of

1 QD-ligand from hSERT proteins can be categorized into roughly two stages where the first 10 2 minutes seems significantly faster. Further analysis in Fig. 3C indicated that a plot of ln(Ft/F0) as 3 a function of time at the initial 10 minutes appear to be linear, a character of first-order 4 dissociation, suggesting the binding valency is monovalent. As illustrated in the figure below, we recognize that it is possible that the displacement in our platform may be indicative of a 5 recognize that it is possible that the displacement in our platform may be indicative of a 6 two-stage dissociation process in which the initial monovalent dissociation is followed by a multivalent dissociation. A solution to resolve this issue is to introduce the monovalent streptavidin conjugated QDs developed by Ting and coworkers.<sup>[5](#page-7-0)</sup> 8





# **Figure S1**



1 2

**Figure S1.** (A) Current response induced by IDT318 ligand incubation. Figure shown here is a representative recording from a single hSERT expressing oocyte voltage-clamped at -60 mV. The 4 representative recording from a single hSERT expressing oocyte voltage-clamped at -60 mV. The<br>5 leakage current profile after incubating with IDT318 displays a typical SERT antagonist 5 leakage current profile after incubating with IDT318 displays a typical SERT antagonist 6 behavior.<sup>7</sup> (5HT: 5-Hydroxytryptamine, serotonin) (B) Comparison of current responses with QD 7 labeling results for the indication of alkyl space participated in ligand binding. We recently<br>8 published the current responses of the IDT318 and its structure-related ligands (left scale) using published the current responses of the IDT318 and its structure-related ligands (left scale) using 9 hSERT expression oocytes. [H](#page-7-0)ere we compared the current responses with QD labeling results 10 (right scale). As can be seen, results generated by both methods show a similar trend as the 11 length of alkyl spacer increases. However, the QD labeling result shows higher sensitivity as 12 evident by a smaller standard deviation. (Fluorescent results: n = 6 oocytes/group; Current results: 13  $n = 4$  oocytes/group)

14 15

# Figure S2



#### 1 2

**Figure S2.** IC<sub>50</sub> measurement of IDT318 ligand. The ability of IDT318 to inhibit the uptake of serotonin was measured by incubating hSERT expressing oocytes in the presence of 50 nM 4 serotonin was measured by incubating hSERT expressing oocytes in the presence of 50 nM<br>5 tritiated serotonin and increasing concentrations of IDT318. The accumulated radioactivity was 5 tritiated serotonin and increasing concentrations of IDT318. The accumulated radioactivity was plotted against concentration of IDT318. The IC<sub>50</sub> of IDT318 was found to be  $3.4 \pm 1.4 \mu M$ 6 plotted against concentration of IDT318. The IC<sub>50</sub> of IDT318 was found to be  $3.4 \pm 1.4 \mu M$ <br>7 (mean  $\pm$  SD).

 $(mean \pm SD)$ .



Figure S3. Displacement of the IDT318 conjugated QD with 10  $\mu$ M paroxetine and 5-HT.

Results are representative micrographs from at least 3 independent experiments.

5

1 2

- <span id="page-7-0"></span>1 References:
- 2
- 3 (1) Tomlinson, I. D.; Iwamoto, H.; Blakely, R. D.; Rosenthal, S. J. *Bioorg. Med. Chem.*
- 4 *Lett.* **2011**, *21*, 1678. 5 (2) Warnement, M. R.; Tomlinson, I. D.; Chang, J. C.; Schreuder, M. A.; Luckabaugh, C. 6 M.; Rosenthal, S. J. *Bioconjug. Chem.* **2008**, *19*, 1404.
- 7 (3) Ramsey, I. S.; DeFelice, L. J. *J. Biol. Chem.* **2002**, *277*, 14475.
- 8 (4) Iwamoto, H.; Blakely, R. D.; De Felice, L. J. *J. Neurosci.* **2006**, *26*, 9851.
- 9 (5) Howarth, M.; Liu, W.; Puthenveetil, S.; Zheng, Y.; Marshall, L. F.; Schmidt, M. M.;
- 10 Wittrup, K. D.; Bawendi, M. G.; Ting, A. Y. *Nat. Methods* **2008**, *5*, 397.
- 11 (6) Mittal, R.; Bruchez, M. P. *Bioconjug Chem* **2011**, *22*, 362.
- 12 (7) Mager, S.; Min, C.; Henry, D. J.; Chavkintt, C.; Hoffman, B. J.; Davidson, N.; Lester, 13 H. A. *Neuron* **1994**, *12*, 845.
- 14
- 15